Afghanistan vs Marshall Islands: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Afghanistan
63.0%
in 2025
Marshall Islands
62.0%
in 2025
Afghanistan rank
142nd
Marshall Islands rank
144th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Afghanistan
- Marshall Islands
How they compare
Afghanistan currently reports 63.0% against 62.0% in Marshall Islands, a difference of 1.0%.
The two have swapped places 7 times across 18 shared years of data; in 2008 it was Marshall Islands ahead.
Afghanistan ranks 142nd and Marshall Islands ranks 144th of 194 countries.
Across the 3 decades both report, Afghanistan averaged higher in 1 and Marshall Islands in 2.
Head to head by decade
| Decade | Afghanistan | Marshall Islands | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 24.5% | 24.5% | Marshall Islands |
| 2010s | 36.3% | 51.4% | 15.1% | Marshall Islands |
| 2020s | 59.2% | 52.3% | 6.8% | Afghanistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Afghanistan or Marshall Islands?
- Afghanistan, at 63.0% against 62.0% in Marshall Islands as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Afghanistan and Marshall Islands?
- 1.0%, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Marshall Islands?
- 18 years are reported by both, from 2008 to 2025.
- How do Afghanistan and Marshall Islands rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Afghanistan ranks 142nd and Marshall Islands ranks 144th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.